person · Reporting owner

Wilson Frank Anders

Disclosed activity across 5 companies

Tapewire entity: 44704
SEC CIK: 0001462948

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Alkermes plc.ALKS · Entity 2392	Director	May 20, 2026	May 23, 2026
CABOT CORPCBT · Entity 4032	Director	January 08, 2026	January 12, 2026
NOVANTA INCNOVT · Entity 3857	Director	January 02, 2026	January 06, 2026
REVVITY, INC.PKI · Entity 3382	Please See Remarks	March 05, 2018	March 06, 2018

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Alkermes plc.

Report date May 20, 2026 · Filed May 23, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	35,751	Ending reported balance After 2026-05-21 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-05-21 · Exercise / conversion · Acquired 6,142 · Balance 37,226 F1: Each restricted stock unit represents a contingent right to receive one ordinary share. Row 2 · 2026-05-21 · Tax withholding · Disposed 1,475 · Balance 35,751
Non Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.98 · Expires 2036-05-20	Direct	11,538	Reported balance After 2026-05-20 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-05-20 · Grant · Acquired 11,538 · Balance 11,538 F2: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant.
Restricted Stock Unit AwardSEC Table II · derivative / convertible security	Direct	5,409	Reported balance After 2026-05-20 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-05-20 · Grant · Acquired 5,409 · Balance 5,409 F1: Each restricted stock unit represents a contingent right to receive one ordinary share. F2: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant.
Restricted Stock Unit AwardSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-05-21 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-05-21 · Exercise / conversion · Disposed 6,142 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one ordinary share. F3: This award is fully vested in accordance with its terms.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one ordinary share.

F2: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant.

F3: This award is fully vested in accordance with its terms.

CABOT CORP

Report date January 08, 2026 · Filed January 12, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	18,552	Reported balance After 2026-01-08 transaction · row 1 1 source row Row 1 · 2026-01-08 · Grant · Acquired 2,298 · Balance 18,552 F1: The shares have been deferred pursuant to Cabot's Non-Employee Directors' Deferral Plan.

Filing footnotes · ownership attribution and instrument terms

F1: The shares have been deferred pursuant to Cabot's Non-Employee Directors' Deferral Plan.

NOVANTA INC

Report date January 02, 2026 · Filed January 06, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	3,947	Reported balance After 2026-01-02 transaction · row 1 1 source row Row 1 · 2026-01-02 · Exercise / conversion · Acquired 1,325 · Balance 3,947 F1: Each Restricted Stock Unit ("RSU") was the economic equivalent of one Novanta Inc. common share. On January 2, 2026, the RSUs were settled in Novanta Inc. common shares.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-01-02 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-01-02 · Exercise / conversion · Disposed 1,325 · Balance 0 F1: Each Restricted Stock Unit ("RSU") was the economic equivalent of one Novanta Inc. common share. On January 2, 2026, the RSUs were settled in Novanta Inc. common shares.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	1,799	Reported balance After 2026-01-02 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-01-02 · Grant · Acquired 1,799 · Balance 1,799 F2: Each Restricted Stock Unit represents the right to receive one Novanta Inc. common share on the first anniversary of the Grant Date (or, if such date is not a business day, on the first business day immediately following the first anniversary of the Grant Date). F3: The Restricted Stock Units were fully vested and non-forfeitable on the Grant Date.

Filing footnotes · ownership attribution and instrument terms

F1: Each Restricted Stock Unit ("RSU") was the economic equivalent of one Novanta Inc. common share. On January 2, 2026, the RSUs were settled in Novanta Inc. common shares.

F2: Each Restricted Stock Unit represents the right to receive one Novanta Inc. common share on the first anniversary of the Grant Date (or, if such date is not a business day, on the first business day immediately following the first anniversary of the Grant Date).

F3: The Restricted Stock Units were fully vested and non-forfeitable on the Grant Date.

REVVITY, INC.

Report date March 05, 2018 · Filed March 06, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	93,624	Reported balance After 2018-03-05 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2018-03-05 · Exercise / conversion · Acquired 31,699 · Balance 93,624
Common StockSEC Table I · non-derivative	Direct	128,738	Reported balance After 2018-03-05 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2018-03-05 · Exercise / conversion · Acquired 35,114 · Balance 128,738
Common StockSEC Table I · non-derivative	Direct	156,754	Reported balance After 2018-03-05 transaction · row 3 Account or security details depend on footnotes; rows are not merged. 1 source row Row 3 · 2018-03-05 · Exercise / conversion · Acquired 28,016 · Balance 156,754
Common StockSEC Table I · non-derivative	Direct	165,581	Reported balance After 2018-03-05 transaction · row 4 Account or security details depend on footnotes; rows are not merged. 1 source row Row 4 · 2018-03-05 · Exercise / conversion · Acquired 8,827 · Balance 165,581
Common StockSEC Table I · non-derivative	Direct	109,654	Reported balance After 2018-03-05 transaction · row 5 Account or security details depend on footnotes; rows are not merged. 1 source row Row 5 · 2018-03-05 · Sale · Disposed 55,627 · Balance 109,654 F1: The sale reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by Mr. Wilson on January 30, 2018. F2: The price reported represents a weighted average sale price of shares sold in multiple transactions at prices ranging from $73.05 to $74.05. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
Common StockSEC Table I · non-derivative	Direct	61,925	Reported balance After 2018-03-05 transaction · row 6 Account or security details depend on footnotes; rows are not merged. 1 source row Row 6 · 2018-03-05 · Sale · Disposed 48,029 · Balance 61,925 F1: The sale reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by Mr. Wilson on January 30, 2018. F3: The price reported represents a weighted average sale price of shares sold in multiple transactions at prices ranging from $74.06 to $74.66. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price. F4: The Reporting Person's direct holdings include shares acquired pursuant to the Reporting Person's (i) election to defer stock and/or compensation into the Deferred Compensation Plan, and/or (ii) reinvestment of dividends relating to the Reporting Person's account.
NQ Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.01 · Expires 2021-02-21	Direct	0	Reported balance After 2018-03-05 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2018-03-05 · Exercise / conversion · Disposed 31,699 · Balance 0 F5: This option became exercisable in three equal annual installments beginning on February 4, 2015, which was the first anniversary of the date on which the option was granted.
NQ Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.26 · Expires 2022-02-03	Direct	0	Reported balance After 2018-03-05 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2018-03-05 · Exercise / conversion · Disposed 35,114 · Balance 0 F6: This option became exercisable in three equal annual installments beginning on February 3, 2016, which was the first anniversary of the date on which the option was granted.
NQ Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.80 · Expires 2023-02-09	Direct	14,008	Reported balance After 2018-03-05 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2018-03-05 · Exercise / conversion · Disposed 28,016 · Balance 14,008 F7: This option became exercisable in three equal annual installments beginning on February 9, 2017, which was the first anniversary of the date on which the option was granted.
NQ Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.65 · Expires 2024-02-07	Direct	17,654	Reported balance After 2018-03-05 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2018-03-05 · Exercise / conversion · Disposed 8,827 · Balance 17,654 F8: This option became exercisable in three equal annual installments beginning on February 7, 2018, which was the first anniversary of the date on which the option was granted.

Filing footnotes · ownership attribution and instrument terms

F1: The sale reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by Mr. Wilson on January 30, 2018.

F2: The price reported represents a weighted average sale price of shares sold in multiple transactions at prices ranging from $73.05 to $74.05. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.

F3: The price reported represents a weighted average sale price of shares sold in multiple transactions at prices ranging from $74.06 to $74.66. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.

F4: The Reporting Person's direct holdings include shares acquired pursuant to the Reporting Person's (i) election to defer stock and/or compensation into the Deferred Compensation Plan, and/or (ii) reinvestment of dividends relating to the Reporting Person's account.

F5: This option became exercisable in three equal annual installments beginning on February 4, 2015, which was the first anniversary of the date on which the option was granted.

F6: This option became exercisable in three equal annual installments beginning on February 3, 2016, which was the first anniversary of the date on which the option was granted.

F7: This option became exercisable in three equal annual installments beginning on February 9, 2017, which was the first anniversary of the date on which the option was granted.

F8: This option became exercisable in three equal annual installments beginning on February 7, 2018, which was the first anniversary of the date on which the option was granted.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

SPARTON CORP

Report date March 04, 2019 · Filed March 04, 2019

Section 16 reporting ended · disclosed 2019-03-04. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2019-03-04 transaction · row 1 1 source row Row 1 · 2019-03-04 · Disposition to issuer · Disposed 7,972 · Balance 0 F1: Disposed of pursuant to Agreement and Plan of Merger dated as of December 11, 2018, by and among Sparton Corporation, Sparton Parent, Inc. and Striker Merger Sub 2018, Inc. in exchange for $18.50 per share in cash, without interest.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to Agreement and Plan of Merger dated as of December 11, 2018, by and among Sparton Corporation, Sparton Parent, Inc. and Striker Merger Sub 2018, Inc. in exchange for $18.50 per share in cash, without interest.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 21, 2026 Filed May 23, 2026 00:06 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionRestricted Stock Unit Award · Derivative	6,142	Not disclosed	Not disclosed	Disclosure SEC source: 0001520262-26-000092 · form4.xml · derivative · entry 5 Wilson Frank Anders · CIK 0001462948 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,142 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F3 · derivative.exercise_date: This award is fully vested in accordance with its terms. F3 · derivative.expiration_date: This award is fully vested in accordance with its terms. Read SEC document
May 21, 2026 Filed May 23, 2026 00:06 UTC	Alkermes plc. ALKS · Entity 2392	Tax withholdingOrdinary Shares	1,475	$36.95	$54,501.25	Disclosure SEC source: 0001520262-26-000092 · form4.xml · nonDerivative · entry 2 Wilson Frank Anders · CIK 0001462948 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,751 Read SEC document
May 21, 2026 Filed May 23, 2026 00:06 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionOrdinary Shares	6,142	Not disclosed	Not disclosed	Disclosure SEC source: 0001520262-26-000092 · form4.xml · nonDerivative · entry 1 Wilson Frank Anders · CIK 0001462948 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,226 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document
May 20, 2026 Filed May 23, 2026 00:06 UTC	Alkermes plc. ALKS · Entity 2392	GrantRestricted Stock Unit Award · Derivative	5,409	$0.00	$0.00	Disclosure SEC source: 0001520262-26-000092 · form4.xml · derivative · entry 4 Wilson Frank Anders · CIK 0001462948 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,409 Underlying: Ordinary Shares · 5,409 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant. F2 · derivative.expiration_date: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant. Read SEC document
May 20, 2026 Filed May 23, 2026 00:06 UTC	Alkermes plc. ALKS · Entity 2392	GrantNon Qualified Stock Option (Right to Buy) · Derivative	11,538	$0.00 Strike: $36.98	$0.00	Disclosure SEC source: 0001520262-26-000092 · form4.xml · derivative · entry 3 Wilson Frank Anders · CIK 0001462948 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,538 Underlying: Ordinary Shares · 11,538 shares Expires 2036-05-20 F2 · derivative.exercise_date: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant. Read SEC document
January 08, 2026 Filed Jan 12, 2026 22:00 UTC	CABOT CORP CBT · Entity 4032	GrantCommon Stock	2,298	$0.00	$0.00	Disclosure SEC source: 0001193125-26-010562 · ownership.xml · nonDerivative · entry 1 Wilson Frank Anders · CIK 0001462948 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,552 F1 · shares: The shares have been deferred pursuant to Cabot's Non-Employee Directors' Deferral Plan. Read SEC document
January 02, 2026 Filed Jan 6, 2026 22:41 UTC	NOVANTA INC NOVT · Entity 3857	GrantRestricted Stock Units · Derivative	1,799	$0.00	$0.00	Disclosure SEC source: 0001076930-26-000021 · form4.xml · derivative · entry 3 Wilson Frank Anders · CIK 0001462948 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,799 Underlying: Common Stock · 1,799 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive one Novanta Inc. common share on the first anniversary of the Grant Date (or, if such date is not a business day, on the first business day immediately following the first anniversary of the Grant Date). F3 · derivative.exercise_date: The Restricted Stock Units were fully vested and non-forfeitable on the Grant Date. F3 · derivative.expiration_date: The Restricted Stock Units were fully vested and non-forfeitable on the Grant Date. Read SEC document
January 02, 2026 Filed Jan 6, 2026 22:41 UTC	NOVANTA INC NOVT · Entity 3857	Exercise / conversionRestricted Stock Units · Derivative	1,325	Not disclosed	Not disclosed	Disclosure SEC source: 0001076930-26-000021 · form4.xml · derivative · entry 2 Wilson Frank Anders · CIK 0001462948 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,325 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") was the economic equivalent of one Novanta Inc. common share. On January 2, 2026, the RSUs were settled in Novanta Inc. common shares. F1 · price: Each Restricted Stock Unit ("RSU") was the economic equivalent of one Novanta Inc. common share. On January 2, 2026, the RSUs were settled in Novanta Inc. common shares. F1 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") was the economic equivalent of one Novanta Inc. common share. On January 2, 2026, the RSUs were settled in Novanta Inc. common shares. F1 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") was the economic equivalent of one Novanta Inc. common share. On January 2, 2026, the RSUs were settled in Novanta Inc. common shares. Read SEC document
January 02, 2026 Filed Jan 6, 2026 22:41 UTC	NOVANTA INC NOVT · Entity 3857	Exercise / conversionCommon Stock	1,325	Not disclosed	Not disclosed	Disclosure SEC source: 0001076930-26-000021 · form4.xml · nonDerivative · entry 1 Wilson Frank Anders · CIK 0001462948 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,947 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") was the economic equivalent of one Novanta Inc. common share. On January 2, 2026, the RSUs were settled in Novanta Inc. common shares. Read SEC document
May 31, 2025 Filed Jun 2, 2025 20:33 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionRestricted Stock Unit Award · Derivative	8,013	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-25-016206 · form4.xml · derivative · entry 3 Wilson Frank Anders · CIK 0001462948 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 8,013 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: This award is fully vested in accordance with its terms. F2 · derivative.expiration_date: This award is fully vested in accordance with its terms. Read SEC document
May 31, 2025 Filed Jun 2, 2025 20:33 UTC	Alkermes plc. ALKS · Entity 2392	Tax withholdingOrdinary Shares	1,924	$30.61	$58,893.64	Disclosure SEC source: 0001127602-25-016206 · form4.xml · nonDerivative · entry 2 Wilson Frank Anders · CIK 0001462948 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,084 Read SEC document
May 31, 2025 Filed Jun 2, 2025 20:33 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionOrdinary Shares	8,013	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-25-016206 · form4.xml · nonDerivative · entry 1 Wilson Frank Anders · CIK 0001462948 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,008 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document
May 21, 2025 Filed May 23, 2025 22:00 UTC	Alkermes plc. ALKS · Entity 2392	GrantRestricted Stock Unit Award · Derivative	6,142	$0.00	$0.00	Disclosure SEC source: 0001127602-25-015544 · form4.xml · derivative · entry 2 Wilson Frank Anders · CIK 0001462948 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,142 Underlying: Ordinary Shares · 6,142 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 5/21/2026. F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 5/21/2026. Read SEC document
May 21, 2025 Filed May 23, 2025 22:00 UTC	Alkermes plc. ALKS · Entity 2392	GrantNon Qualified Stock Option (Right to Buy) · Derivative	13,474	$0.00 Strike: $30.53	$0.00	Disclosure SEC source: 0001127602-25-015544 · form4.xml · derivative · entry 1 Wilson Frank Anders · CIK 0001462948 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,474 Underlying: Ordinary Shares · 13,474 shares Expires 2035-05-21 F1 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 5/21/2026. Read SEC document
January 10, 2025 Filed Jan 14, 2025 22:30 UTC	CABOT CORP CBT · Entity 4032	GrantCommon Stock	1,788	$0.00	$0.00	Disclosure SEC source: 0000950170-25-005480 · ownership.xml · nonDerivative · entry 1 Wilson Frank Anders · CIK 0001462948 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,254 F1 · shares: The shares have been deferred pursuant to Cabot's Non-Employee Directors' Deferral Plan. Read SEC document
January 02, 2025 Filed Jan 6, 2025 21:35 UTC	NOVANTA INC NOVT · Entity 3857	GrantRestricted Stock Units · Derivative	1,325	$0.00	$0.00	Disclosure SEC source: 0001127602-25-000779 · form4.xml · derivative · entry 3 Wilson Frank Anders · CIK 0001462948 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,325 Underlying: Common Stock · 1,325 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive one Novanta Inc. common share on the first anniversary of the Grant Date (or, if such date is not a business day, on the first business day immediately following the first anniversary of the Grant Date). F2 · derivative.exercise_date: Each Restricted Stock Unit represents the right to receive one Novanta Inc. common share on the first anniversary of the Grant Date (or, if such date is not a business day, on the first business day immediately following the first anniversary of the Grant Date). F3 · derivative.exercise_date: The Restricted Stock Units were fully vested and non forfeitable on the Grant Date. F2 · derivative.expiration_date: Each Restricted Stock Unit represents the right to receive one Novanta Inc. common share on the first anniversary of the Grant Date (or, if such date is not a business day, on the first business day immediately following the first anniversary of the Grant Date). F3 · derivative.expiration_date: The Restricted Stock Units were fully vested and non forfeitable on the Grant Date. Read SEC document
January 02, 2025 Filed Jan 6, 2025 21:35 UTC	NOVANTA INC NOVT · Entity 3857	Exercise / conversionRestricted Stock Units · Derivative	1,217	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-25-000779 · form4.xml · derivative · entry 2 Wilson Frank Anders · CIK 0001462948 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,217 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") was the economic equivalent of one Novanta Inc. common share. On January 2, 2025, the RSUs were settled in Novanta Inc. common shares. F1 · price: Each Restricted Stock Unit ("RSU") was the economic equivalent of one Novanta Inc. common share. On January 2, 2025, the RSUs were settled in Novanta Inc. common shares. F1 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") was the economic equivalent of one Novanta Inc. common share. On January 2, 2025, the RSUs were settled in Novanta Inc. common shares. F1 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") was the economic equivalent of one Novanta Inc. common share. On January 2, 2025, the RSUs were settled in Novanta Inc. common shares. Read SEC document
January 02, 2025 Filed Jan 6, 2025 21:35 UTC	NOVANTA INC NOVT · Entity 3857	Exercise / conversionCommon Stock	1,217	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-25-000779 · form4.xml · nonDerivative · entry 1 Wilson Frank Anders · CIK 0001462948 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,622 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") was the economic equivalent of one Novanta Inc. common share. On January 2, 2025, the RSUs were settled in Novanta Inc. common shares. Read SEC document
July 03, 2024 Filed Jul 8, 2024 20:55 UTC	NOVANTA INC NOVT · Entity 3857	Exercise / conversionRestricted Stock Units · Derivative	278	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-24-020184 · form4.xml · derivative · entry 2 Wilson Frank Anders · CIK 0001462948 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 278 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") was the economic equivalent of one Novanta Inc. common share. On July 3, 2024, the RSUs were settled in Novanta Inc. common shares. F1 · price: Each Restricted Stock Unit ("RSU") was the economic equivalent of one Novanta Inc. common share. On July 3, 2024, the RSUs were settled in Novanta Inc. common shares. F1 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") was the economic equivalent of one Novanta Inc. common share. On July 3, 2024, the RSUs were settled in Novanta Inc. common shares. F1 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") was the economic equivalent of one Novanta Inc. common share. On July 3, 2024, the RSUs were settled in Novanta Inc. common shares. Read SEC document
July 03, 2024 Filed Jul 8, 2024 20:55 UTC	NOVANTA INC NOVT · Entity 3857	Exercise / conversionCommon Stock	278	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-24-020184 · form4.xml · nonDerivative · entry 1 Wilson Frank Anders · CIK 0001462948 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,405 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") was the economic equivalent of one Novanta Inc. common share. On July 3, 2024, the RSUs were settled in Novanta Inc. common shares. Read SEC document
June 29, 2024 Filed Jul 1, 2024 21:02 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionRestricted Stock Unit Award · Derivative	6,104	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-24-019607 · form4.xml · derivative · entry 3 Wilson Frank Anders · CIK 0001462948 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,104 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: This award is fully vested in accordance with its terms. F2 · derivative.expiration_date: This award is fully vested in accordance with its terms. Read SEC document
June 29, 2024 Filed Jul 1, 2024 21:02 UTC	Alkermes plc. ALKS · Entity 2392	Tax withholdingOrdinary Shares	1,465	$24.10	$35,306.50	Disclosure SEC source: 0001127602-24-019607 · form4.xml · nonDerivative · entry 2 Wilson Frank Anders · CIK 0001462948 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,995 Read SEC document
June 29, 2024 Filed Jul 1, 2024 21:02 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionOrdinary Shares	6,104	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-24-019607 · form4.xml · nonDerivative · entry 1 Wilson Frank Anders · CIK 0001462948 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,460 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document
May 31, 2024 Filed Jun 4, 2024 21:03 UTC	Alkermes plc. ALKS · Entity 2392	GrantNon Qualified Stock Option (Right to Buy) · Derivative	17,492	$0.00 Strike: $23.40	$0.00	Disclosure SEC source: 0001127602-24-017731 · form4.xml · derivative · entry 10 Wilson Frank Anders · CIK 0001462948 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,492 Underlying: Ordinary Shares · 17,492 shares Expires 2034-05-31 F7 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 5/31/2025. Read SEC document
May 31, 2024 Filed Jun 4, 2024 21:03 UTC	Alkermes plc. ALKS · Entity 2392	GrantRestricted Stock Unit Award · Derivative	8,013	$0.00	$0.00	Disclosure SEC source: 0001127602-24-017731 · form4.xml · derivative · entry 9 Wilson Frank Anders · CIK 0001462948 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,013 Underlying: Ordinary Shares · 8,013 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F6 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 5/31/2025. F6 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 5/31/2025. Read SEC document
January 11, 2024 Filed Jan 12, 2024 21:30 UTC	CABOT CORP CBT · Entity 4032	GrantCommon Stock	2,035	$0.00	$0.00	Disclosure SEC source: 0000950170-24-004257 · ownership.xml · nonDerivative · entry 1 Wilson Frank Anders · CIK 0001462948 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,466 F1 · shares: The shares have been deferred pursuant to Cabot's Non-Employee Directors' Deferral Plan. Read SEC document
January 03, 2024 Filed Jan 4, 2024 21:58 UTC	NOVANTA INC NOVT · Entity 3857	Exercise / conversionRestricted Stock Units · Derivative	464	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-24-000860 · form4.xml · derivative · entry 3 Wilson Frank Anders · CIK 0001462948 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 464 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") was the economic equivalent of one Novanta Inc. common share. On January 3, 2024, the RSUs were settled in Novanta Inc. common shares. F1 · price: Each Restricted Stock Unit ("RSU") was the economic equivalent of one Novanta Inc. common share. On January 3, 2024, the RSUs were settled in Novanta Inc. common shares. F1 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") was the economic equivalent of one Novanta Inc. common share. On January 3, 2024, the RSUs were settled in Novanta Inc. common shares. F1 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") was the economic equivalent of one Novanta Inc. common share. On January 3, 2024, the RSUs were settled in Novanta Inc. common shares. Read SEC document
January 03, 2024 Filed Jan 4, 2024 21:58 UTC	NOVANTA INC NOVT · Entity 3857	Exercise / conversionCommon Stock	464	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-24-000860 · form4.xml · nonDerivative · entry 1 Wilson Frank Anders · CIK 0001462948 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,127 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") was the economic equivalent of one Novanta Inc. common share. On January 3, 2024, the RSUs were settled in Novanta Inc. common shares. Read SEC document
January 02, 2024 Filed Jan 4, 2024 21:58 UTC	NOVANTA INC NOVT · Entity 3857	GrantRestricted Stock Units · Derivative	1,217	$0.00	$0.00	Disclosure SEC source: 0001127602-24-000860 · form4.xml · derivative · entry 2 Wilson Frank Anders · CIK 0001462948 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,217 Underlying: Common Stock · 1,217 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive one Novanta Inc. common share on the first anniversary of the Grant Date (or, if such date is not a business day, on the first business day immediately following the first anniversary of the Grant Date). F2 · derivative.exercise_date: Each Restricted Stock Unit represents the right to receive one Novanta Inc. common share on the first anniversary of the Grant Date (or, if such date is not a business day, on the first business day immediately following the first anniversary of the Grant Date). F3 · derivative.exercise_date: The Restricted Stock Units were fully vested and non forfeitable on the Grant Date. F2 · derivative.expiration_date: Each Restricted Stock Unit represents the right to receive one Novanta Inc. common share on the first anniversary of the Grant Date (or, if such date is not a business day, on the first business day immediately following the first anniversary of the Grant Date). F3 · derivative.expiration_date: The Restricted Stock Units were fully vested and non forfeitable on the Grant Date. Read SEC document
November 17, 2023 Filed Jun 4, 2024 21:03 UTC	Alkermes plc. ALKS · Entity 2392	OtherRestricted Stock Unit Award · Derivative	119	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-24-017731 · form4.xml · derivative · entry 8 Wilson Frank Anders · CIK 0001462948 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,104 Underlying: Ordinary Shares · 119 shares Expires not disclosed F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F4 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F5 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 6/29/2024. F5 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 6/29/2024. Read SEC document
November 17, 2023 Filed Jun 4, 2024 21:03 UTC	Alkermes plc. ALKS · Entity 2392	OtherNon Qualified Stock Option (Right to Buy) · Derivative	254	$30.72 Strike: $30.72	$7,802.88	Disclosure SEC source: 0001127602-24-017731 · form4.xml · derivative · entry 7 Wilson Frank Anders · CIK 0001462948 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,986 Underlying: Ordinary Shares · 254 shares Expires 2033-06-29 F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F3 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 6/29/2024. Read SEC document
November 17, 2023 Filed Jun 4, 2024 21:03 UTC	Alkermes plc. ALKS · Entity 2392	OtherNon Qualified Stock Option (Right to Buy) · Derivative	231	$30.86 Strike: $30.86	$7,128.66	Disclosure SEC source: 0001127602-24-017731 · form4.xml · derivative · entry 6 Wilson Frank Anders · CIK 0001462948 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,785 Underlying: Ordinary Shares · 231 shares Expires 2032-07-07 F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F2 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document
November 17, 2023 Filed Jun 4, 2024 21:03 UTC	Alkermes plc. ALKS · Entity 2392	OtherNon Qualified Stock Option (Right to Buy) · Derivative	313	$24.24 Strike: $24.24	$7,587.12	Disclosure SEC source: 0001127602-24-017731 · form4.xml · derivative · entry 5 Wilson Frank Anders · CIK 0001462948 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,990 Underlying: Ordinary Shares · 313 shares Expires 2031-06-14 F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F2 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document
November 17, 2023 Filed Jun 4, 2024 21:03 UTC	Alkermes plc. ALKS · Entity 2392	OtherNon Qualified Stock Option (Right to Buy) · Derivative	230	$18.45 Strike: $18.45	$4,243.50	Disclosure SEC source: 0001127602-24-017731 · form4.xml · derivative · entry 4 Wilson Frank Anders · CIK 0001462948 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,739 Underlying: Ordinary Shares · 230 shares Expires 2030-12-02 F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F2 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document
November 17, 2023 Filed Jun 4, 2024 21:03 UTC	Alkermes plc. ALKS · Entity 2392	OtherNon Qualified Stock Option (Right to Buy) · Derivative	256	$16.52 Strike: $16.52	$4,229.12	Disclosure SEC source: 0001127602-24-017731 · form4.xml · derivative · entry 3 Wilson Frank Anders · CIK 0001462948 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,079 Underlying: Ordinary Shares · 256 shares Expires 2030-05-20 F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F2 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document
November 17, 2023 Filed Jun 4, 2024 21:03 UTC	Alkermes plc. ALKS · Entity 2392	OtherNon Qualified Stock Option (Right to Buy) · Derivative	224	$20.81 Strike: $20.81	$4,661.44	Disclosure SEC source: 0001127602-24-017731 · form4.xml · derivative · entry 2 Wilson Frank Anders · CIK 0001462948 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,424 Underlying: Ordinary Shares · 224 shares Expires 2029-12-04 F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F2 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document
November 17, 2023 Filed Jun 4, 2024 21:03 UTC	Alkermes plc. ALKS · Entity 2392	OtherNon Qualified Stock Option (Right to Buy) · Derivative	1,236	$20.81 Strike: $20.81	$25,721.16	Disclosure SEC source: 0001127602-24-017731 · form4.xml · derivative · entry 1 Wilson Frank Anders · CIK 0001462948 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,036 Underlying: Ordinary Shares · 1,236 shares Expires 2029-12-04 F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F2 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document
July 07, 2023 Filed Jul 11, 2023 00:36 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionRestricted Stock Unit Award · Derivative	5,957	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-23-020551 · form4.xml · derivative · entry 3 Wilson Frank Anders · CIK 0001462948 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 5,957 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: This award is fully vested in accordance with its terms. F2 · derivative.expiration_date: This award is fully vested in accordance with its terms. Read SEC document
July 07, 2023 Filed Jul 11, 2023 00:36 UTC	Alkermes plc. ALKS · Entity 2392	Tax withholdingOrdinary Shares	1,430	$29.88	$42,728.40	Disclosure SEC source: 0001127602-23-020551 · form4.xml · nonDerivative · entry 2 Wilson Frank Anders · CIK 0001462948 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,356 Read SEC document
July 07, 2023 Filed Jul 11, 2023 00:36 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionOrdinary Shares	5,957	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-23-020551 · form4.xml · nonDerivative · entry 1 Wilson Frank Anders · CIK 0001462948 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,786 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document
July 03, 2023 Filed Jul 6, 2023 20:37 UTC	NOVANTA INC NOVT · Entity 3857	GrantRestricted Stock Units · Derivative	278	$0.00	$0.00	Disclosure SEC source: 0001127602-23-020418 · form4.xml · derivative · entry 1 Wilson Frank Anders · CIK 0001462948 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 278 Underlying: Common Stock · 278 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive one Novanta Inc. common share on the first anniversary of the Grant Date (or, if such date is not a business day, on the first business day immediately following the first anniversary of the Grant Date). F1 · derivative.exercise_date: Each Restricted Stock Unit represents the right to receive one Novanta Inc. common share on the first anniversary of the Grant Date (or, if such date is not a business day, on the first business day immediately following the first anniversary of the Grant Date). F2 · derivative.exercise_date: The Restricted Stock Units were fully vested and non-forfeitable on the Grant Date. F1 · derivative.expiration_date: Each Restricted Stock Unit represents the right to receive one Novanta Inc. common share on the first anniversary of the Grant Date (or, if such date is not a business day, on the first business day immediately following the first anniversary of the Grant Date). F2 · derivative.expiration_date: The Restricted Stock Units were fully vested and non-forfeitable on the Grant Date. Read SEC document
June 29, 2023 Filed Jun 30, 2023 20:36 UTC	Alkermes plc. ALKS · Entity 2392	GrantRestricted Stock Unit Award · Derivative	5,985	$0.00	$0.00	Disclosure SEC source: 0001127602-23-019634 · form4.xml · derivative · entry 2 Wilson Frank Anders · CIK 0001462948 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,985 Underlying: Ordinary Shares · 5,985 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 6/29/2024. F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 6/29/2024. Read SEC document
June 29, 2023 Filed Jun 30, 2023 20:36 UTC	Alkermes plc. ALKS · Entity 2392	GrantNon Qualified Stock Option (Right to Buy) · Derivative	12,732	$0.00 Strike: $31.33	$0.00	Disclosure SEC source: 0001127602-23-019634 · form4.xml · derivative · entry 1 Wilson Frank Anders · CIK 0001462948 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,732 Underlying: Ordinary Shares · 12,732 shares Expires 2033-06-29 F1 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 6/29/2024. Read SEC document
January 12, 2023 Filed Jan 13, 2023 21:05 UTC	CABOT CORP CBT · Entity 4032	GrantCommon Stock	1,854	$0.00	$0.00	Disclosure SEC source: 0001209191-23-003264 · doc4.xml · nonDerivative · entry 1 Wilson Frank Anders · CIK 0001462948 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,431 F1 · shares: The shares have been deferred pursuant to Cabot's Non-Employee Directors' Deferral Plan. Read SEC document
January 03, 2023 Filed Jan 5, 2023 21:42 UTC	NOVANTA INC NOVT · Entity 3857	GrantDeferred Stock Units · Derivative	520	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-23-000894 · form4.xml · derivative · entry 4 Wilson Frank Anders · CIK 0001462948 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,223 Underlying: Common Stock · 520 shares Expires not disclosed F4 · derivative.exercise_price: As of the date the reporting person ceases to be a director of the issuer, each Deferred Stock Unit will convert into a share of issuer common stock. The Deferred Stock Units were fully vested and non-forfeitable on the Grant Date. F4 · price: As of the date the reporting person ceases to be a director of the issuer, each Deferred Stock Unit will convert into a share of issuer common stock. The Deferred Stock Units were fully vested and non-forfeitable on the Grant Date. F4 · derivative.exercise_date: As of the date the reporting person ceases to be a director of the issuer, each Deferred Stock Unit will convert into a share of issuer common stock. The Deferred Stock Units were fully vested and non-forfeitable on the Grant Date. F4 · derivative.expiration_date: As of the date the reporting person ceases to be a director of the issuer, each Deferred Stock Unit will convert into a share of issuer common stock. The Deferred Stock Units were fully vested and non-forfeitable on the Grant Date. Read SEC document
January 03, 2023 Filed Jan 5, 2023 21:42 UTC	NOVANTA INC NOVT · Entity 3857	GrantRestricted Stock Units · Derivative	464	$0.00	$0.00	Disclosure SEC source: 0001127602-23-000894 · form4.xml · derivative · entry 3 Wilson Frank Anders · CIK 0001462948 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 464 Underlying: Common Stock · 464 shares Expires not disclosed F2 · security: Each Restricted Stock Unit represents the right to receive one Novanta Inc. common share on the first anniversary of the Grant Date (or, if such date is not a business day, on the first business day immediately following the first anniversary of the Grant Date). F2 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive one Novanta Inc. common share on the first anniversary of the Grant Date (or, if such date is not a business day, on the first business day immediately following the first anniversary of the Grant Date). F2 · derivative.exercise_date: Each Restricted Stock Unit represents the right to receive one Novanta Inc. common share on the first anniversary of the Grant Date (or, if such date is not a business day, on the first business day immediately following the first anniversary of the Grant Date). F3 · derivative.exercise_date: The Restricted Stock Units were fully vested and non-forfeitable on the Grant Date. F2 · derivative.expiration_date: Each Restricted Stock Unit represents the right to receive one Novanta Inc. common share on the first anniversary of the Grant Date (or, if such date is not a business day, on the first business day immediately following the first anniversary of the Grant Date). F3 · derivative.expiration_date: The Restricted Stock Units were fully vested and non-forfeitable on the Grant Date. Read SEC document
January 03, 2023 Filed Jan 5, 2023 21:42 UTC	NOVANTA INC NOVT · Entity 3857	Exercise / conversionRestricted Stock Units · Derivative	359	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-23-000894 · form4.xml · derivative · entry 2 Wilson Frank Anders · CIK 0001462948 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 359 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each Restricted Stock Unit ("RSU") was the economic equivalent of one Novanta Inc. common share. On January 3, 2023, the RSUs were settled in Novanta Inc. common shares. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") was the economic equivalent of one Novanta Inc. common share. On January 3, 2023, the RSUs were settled in Novanta Inc. common shares. F1 · price: Each Restricted Stock Unit ("RSU") was the economic equivalent of one Novanta Inc. common share. On January 3, 2023, the RSUs were settled in Novanta Inc. common shares. F1 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") was the economic equivalent of one Novanta Inc. common share. On January 3, 2023, the RSUs were settled in Novanta Inc. common shares. F1 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") was the economic equivalent of one Novanta Inc. common share. On January 3, 2023, the RSUs were settled in Novanta Inc. common shares. Read SEC document
January 03, 2023 Filed Jan 5, 2023 21:42 UTC	NOVANTA INC NOVT · Entity 3857	Exercise / conversionCommon Stock	359	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-23-000894 · form4.xml · nonDerivative · entry 1 Wilson Frank Anders · CIK 0001462948 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 663 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") was the economic equivalent of one Novanta Inc. common share. On January 3, 2023, the RSUs were settled in Novanta Inc. common shares. Read SEC document
July 07, 2022 Filed Jul 8, 2022 20:24 UTC	Alkermes plc. ALKS · Entity 2392	GrantNon Qualified Stock Option (Right to Buy) · Derivative	11,554	$0.00 Strike: $31.48	$0.00	Disclosure SEC source: 0001127602-22-019133 · form4.xml · derivative · entry 2 Wilson Frank Anders · CIK 0001462948 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,554 Underlying: Ordinary Shares · 11,554 shares Expires 2032-07-07 F3 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 7/7/2023. Read SEC document
July 07, 2022 Filed Jul 8, 2022 20:24 UTC	Alkermes plc. ALKS · Entity 2392	GrantRestricted Stock Unit Award · Derivative	5,957	$0.00	$0.00	Disclosure SEC source: 0001127602-22-019133 · form4.xml · derivative · entry 1 Wilson Frank Anders · CIK 0001462948 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,957 Underlying: Ordinary Shares · 5,957 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 7/7/2023. F2 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 7/7/2023. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.